Summit Financial’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Summit Financial’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.02M	Buy	31,510 +2,913	+10%	+$364K	0.05%	373
2025 Q4	$3.49M	Buy	28,597 +24,133	+541%	+$2.77M	0.05%	341
2025 Q3	$447K	Sell	4,464 -1,139	-20%	-$103K	0.01%	915
2025 Q2	$465K	Sell	5,603 -706	-11%	-$56.3K	0.01%	585
2025 Q1	$512K	Sell	6,309 -73	-1%	-$6.53K	0.01%	507
2024 Q4	$575K	Sell	6,382 -248	-4%	-$24K	0.02%	423
2024 Q3	$655K	Sell	6,630 -495	-7%	-$48.6K	0.03%	327
2024 Q2	$661K	Sell	7,125 -2,027	-22%	-$182K	0.03%	281
2024 Q1	$868K	Buy	9,152 +4,269	+87%	+$396K	0.05%	202
2023 Q4	$436K	Buy	4,883 +1,101	+29%	+$81.8K	0.03%	260
2023 Q3	$276K	Hold	3,782	–	–	0.02%	294
2023 Q2	$315K	Buy	+3,782	New	+$316K	0.02%	272

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Summit Financial's XBI Position: Q1 2026 in Review

Summit Financial increased its State Street SPDR S&P Biotech ETF (XBI) stake by 10% in Q1 2026, buying an estimated $364K and bringing the position to 31,510 shares worth $4.02M. The position accounts for 0.05% of the portfolio, ranked #373.

Summit Financial first reported a position in XBI in Q2 2023 and has held it in 12 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Summit Financial held 31,510 shares of State Street SPDR S&P Biotech ETF worth $4.02M as of Q1 2026.
Summit Financial bought 2,913 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $364K.
State Street SPDR S&P Biotech ETF made up 0.05% of Summit Financial's portfolio in Q1 2026, its #373 holding.
Summit Financial first reported a position in State Street SPDR S&P Biotech ETF in Q2 2023 and has held it in 12 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Summit Financial's 13F filing for Q1 2026, filed 15 May 2026.